Swedish 3D bioprinter provider CELLINK has released details of a partnership with French regenerative medicine research and development companyCTI生物技术。
CTI Biotech是完全许可的人体组织生物库，正在使用Cellink 3D生物生物发电机在LAB中创建肿瘤组织模型，并研究针对癌症患者的新疗法。
CTI Biotech的创始人Colin McGuckin教授说：“我们很荣幸能与Cellink合作，以推进我们在癌症个性化医学领域的3D印刷技术。”
Tour of the BIO X 3D bioprinter, as used in CTI BIOTECH research. CLip viaCellink 3D在YouTube上。
在细胞水平上了解癌症
自Cellink宣布推出它的发射已有将近一年latest 3D bioprinter – the BIO X。现在安装在CTI Biotech的实验室中，生物X将与从癌症患者肿瘤的组织样品中提取的细胞一起工作。
Combined with a supportive material, i.e.a hydrogel, these cells will be 3D printed into live replica tumors that can be used to test response to new treatments.
希望这些模型能够降低临床前药物筛查的昂贵40％+流失率。根据麦加金教授的说法，“癌症疗法受到我们对3D肿瘤中癌症如何生长的理解的严重限制。”
3D生物打印和癌症
A number of international research institutions, including the印度技术学院海得拉巴andKU Leuven已经evaluating the value of 3D bioprinting for cancer researchin recent years.
维克森林再生医学研究所（WFIRM）正在使用其车身芯片设备测试该疾病的新药，甚至NASA在太空中采用了3D生物发电机测试癌组织模型的制造。
Better treatments for unpredictable diseases
Erik Gatenholm, co-founder and CEO of CELLINK comments, “We are always excited when our technologies are used to accelerate research and enable new advancements,”
“The oncology research field is one of the major focus areas for us and we see a strong benefit of using our bioprinting platform to develop better and more realistic cancer tissue models so that we can develop better treatments.”
In November 2017, CELLINK also received €350,000 ($417,889 USD) from the European Union’s Horizon 2020 initiative. Together with 5 other partners, CELLINK will be working on the SilkFUSION project to genetically engineer platelets for “transfusion and drug research.”
Stay up to date with all the latest 3D bioprinting developments atTwitter上的3D印刷行业andFacebook。在这里订阅我们的常规新闻通讯。
Did this research or the teams involved catch your eye? Make sure they get recognized in the second annual 3D Printing Industry andnominate them here.
特色图显示了样品3D生物打印耳模型。通过Cellink照片
